Kadmon Pharmaceuticals

REACH SVR Registry

The REACH SVR Registry is a prospective clinical study designed to evaluate the safety, adherence, and efficacy of prescribed, patient-administered therapy with Infergen® (Interferon alfacon-1) and other prescribed therapies in patients chronically infected with HCV.

To learn more about the REACH SVR Registry, visit the following website: www.clinicaltrials.gov


Begin typing your search term above and press enter to search. Press ESC to cancel.

Back To Top